Genocea Biosciences Inc
OTC:GNCAQ

Watchlist Manager
Genocea Biosciences Inc Logo
Genocea Biosciences Inc
OTC:GNCAQ
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 58.8 USD

Operating Margin

-3 174.5%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 174.5%
=
Operating Income
$-52.1m
/
Revenue
$1.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 174.5%
=
Operating Income
$-52.1m
/
Revenue
$1.6m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Genocea Biosciences Inc
OTC:GNCAQ
58.8 USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
386.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
163.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.6B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.4B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-3 174.5%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Genocea Biosciences Inc
Glance View

Market Cap
58.8 USD
Industry
Biotechnology

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is focused on discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Its product candidates include GEN-011 and GEN-009. GEN-011 is an investigational solid tumor cell therapy candidate, which consists of CD4+ and CD8+ neoantigen-targeted peripheral T cells (NPTs) which are specific for up to 30 antigens, designed to limit tumor escape. GEN-011 consists of T cells extracted from the patient’s peripheral blood and specific for ATLAS-prioritized neoantigens. GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The firm is evaluating its Phase I/IIa of GEN-009.

GNCAQ Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-3 174.5%
=
Operating Income
$-52.1m
/
Revenue
$1.6m
How has Operating Margin changed over time?

Over the last 1 years, Genocea Biosciences Inc’s Operating Margin has increased from -3 457.6% to -3 174.5%. During this period, it reached a low of -3 457.6% on Dec 31, 2020 and a high of -3 174.5% on Jan 31, 2022.

Back to Top